Sebelipase alfa

Sebelipase alfa (pronunciation: se-BEL-i-pase AL-fa) is a recombinant form of the human lysosomal acid lipase enzyme. It is used as a replacement therapy for the treatment of lysosomal acid lipase deficiency (LAL-D), a rare genetic disorder.

Etymology

The name "Sebelipase alfa" is derived from the Greek words "sebo" meaning fat, "lipase" referring to the enzyme that breaks down fats, and "alfa" indicating that it is a form of the enzyme.

Usage

Sebelipase alfa is used to treat lysosomal acid lipase deficiency (LAL-D), a rare genetic disorder that prevents the body from producing enough of the enzyme lysosomal acid lipase. This enzyme is necessary for the breakdown and removal of certain fats (cholesterol and triglycerides) in the body. Without enough of this enzyme, these fats can build up in the body's cells, causing a variety of health problems.

Administration

Sebelipase alfa is administered by intravenous infusion, typically once every other week. The dosage is based on the patient's weight and the severity of their condition.

Side Effects

Common side effects of sebelipase alfa include fever, headache, vomiting, and diarrhea. More serious side effects can include allergic reactions, such as difficulty breathing or swelling of the face, lips, tongue, or throat.